Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer
Current Oncology · 2026
DOI: 10.3390/curroncol33100600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Yawei Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Chemoembolization, Therapeutic, Lung Neoplasms, Bronchial Arteries. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the CAMS Innovation Fund for Medical Sciences (CIFMS), the Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital.
Abstract (Originalsprache)
Objective
This study mainly focused on evaluating the efficacy and safety of drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) in treating advanced refractory non-small cell lung cancer (NSCLC) patients, with an exploratory investigation of whether combining DEB-BACE with anlotinib could bring additional benefits and identification of key prognostic factors.
Methods
A retrospective analysis was conducted on 104 eligible patients, including 64 who received DEB-BACE monotherapy and 40 who received DEB-BACE combined with anlotinib. Kaplan–Meier method, log-rank test, and Cox proportional hazard model were used for survival and prognostic analyses. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).
Results
The entire cohort had a median PFS of 13.9 months and median OS of 17.0 months, suggesting a potential survival benefit of DEB-BACE in advanced NSCLC. As an exploratory analysis, the combination group showed numerical advantages in PFS (13.9 vs. 10.6 months), OS (20.3 vs. 14.0 months), and ORR, without significant differences (all p > 0.05). ECOG 2 was an independent poor prognostic factor for PFS (HR = 2.602, p = 0.020) and tended to affect OS (HR = 2.259, p = 0.050). No grade 4 AEs or treatment-related deaths occurred; the 5.8% grade 3 AEs were all manageable.
Conclusions
DEB-BACE may be effective and safe as a treatment option for advanced NSCLC patients, although prospective controlled studies are needed to confirm these findings. The combination of DEB-BACE with anlotinib, as an exploratory strategy, shows numerical benefits but no significant superiority.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Förderung
- National Natural Science Foundation of China
- the CAMS Innovation Fund for Medical Sciences (CIFMS)
- the Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital
Zitieren
APA
Li, Y., Xi, J., Liu, Y., Li, X., & Zhang, X. (2026). Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer. Current Oncology. https://doi.org/10.3390/curroncol33100600
Vancouver
Li Y, Xi J, Liu Y, Li X, Zhang X. Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer. Current Oncology. 2026. doi:10.3390/curroncol33100600
BibTeX
@article{Li2026,
author = {Li, Yawei and Xi, Junqing and Liu, Yuxi and Li, Xiao and Zhang, Xiaowu},
title = {Clinical Utility of Drug-Eluting Beads Bronchial Arterial Chemoembolization in Advanced Refractory Non-Small Cell Lung Cancer},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33100600}
}
EUVIMED